Skip to main content
. 2020 Nov 19;10:20149. doi: 10.1038/s41598-020-76864-y

Figure 4.

Figure 4

Subcutaneous injection of Cl-amidine decreases psoriasis-like lesions in Il36rn−/− mice. (A) Protocols for the development of imiquimod (IMQ)-induced psoriasis-like lesions. For prevention experiments, Il36rn−/− mice were subcutaneously injected with Cl-amidine (10 mg/kg) 4 h before IMQ treatment (days 1–3). (B) Representative clinical images of back skin and histological images of skin sections from Il36rn−/− mice treated with Cl-amidine or vehicle 3 days after IMQ challenge. Scale bars, 100 µm. (C) Left: psoriasis area and severity index (PASI) scores of skin lesions in IMQ-challenged mice treated with Cl-amidine or vehicle on day 4 (Mann–Whitney U test, n = 6 animals/group; **p < 0. 01 versus vehicle-treated Il36rn−/− mice). Second from left: the area of the epidermis within a distance of 10 mm was measured using ImageJ software. Third from left: number of MPO+ cells/high-power field in back skin cross-sections from Cl-amidine- or vehicle-treated Il36rn−/− mice (100 × magnification, nine sections per mouse, Mann–Whitney U test, n = 6 animals/group; **p < 0.05 versus vehicle-treated Il36rn−/− mice). Right: area of NETs/high-power field in back skin cross-sections from Cl-amidine- or vehicle-treated Il36rn−/− mice (40 × magnification, nine sections per mouse, Mann–Whitney U test, n = 6 animals/group; **p < 0.05 versus vehicle-treated Il36rn-/- mice). (D) Real time RT-PCR analyses of psoriasis-related cytokines and chemokines from mouse skin samples (Mann–Whitney U test, n = 6 animals/group *p < 0.05, **p < 0.01 versus vehicle-treated Il36rn−/− mice). Data were expressed relative to GAPDH levels.